MASP1: A Potential Drug Target and Biomarker (G5648)

Target Name: MASP1

NCBI ID: G5648

MASP1

MASP1: A Potential Drug Target and Biomarker

Mannan-binding lectin serine protease 1 (MASP1) is a protein that plays a crucial role in the immune system. MASP1 is a member of the mannan-binding lectin (MBL) family, which consists of various proteins that are involved in the recognition of pathogens and other foreign substances in the body. MASP1 is expressed in various tissues and cells, including blood cells, tissues, and organs, and it has been implicated in the immune response, inflammation, and fibrosis.

Recent studies have suggested that MASP1 may have potential as a drug target or biomarker. MASP1 has been shown to play a role in the regulation of inflammation and has been linked to various inflammatory diseases, including cancer, autoimmune diseases, and chronic obstructive pulmonary disease (COPD). In addition, MASP1 has also been shown to be involved in the regulation of cell cycle progression and has been linked to the development of various types of cancer.

One of the potential reasons for the potential drug targeting of MASP1 is its role in the regulation of the immune response. MASP1 has been shown to play a negative role in the regulation of T cell proliferation and has been linked to the development of various types of cancer. In addition, MASP1 has also been shown to play a role in the regulation of B cell development and has been linked to the development of autoimmune diseases.

Another potential reason for the potential drug targeting of MASP1 is its role in the regulation of cell cycle progression. MASP1 has been shown to play a role in the regulation of cell cycle progression and has been linked to the development of various types of cancer. In addition, MASP1 has also been shown to play a role in the regulation of microtubule dynamics and has been linked to the development of neurodegenerative diseases.

In addition to its potential drug targeting and biomarker properties, MASP1 has also been shown to have potential as a diagnostic tool. Several studies have shown that MASP1 is often expressed in various types of cancer and that its expression levels can be used as a diagnostic marker for various types of cancer, including breast, lung, and ovarian cancer.

In conclusion, MASP1 is a protein that has been shown to play a crucial role in the immune system and has potential as a drug target or biomarker. Further research is needed to fully understand the role of MASP1 in the immune system and its potential as a drug target or biomarker.

Protein Name: MBL Associated Serine Protease 1

Functions: Functions in the lectin pathway of complement, which performs a key role in innate immunity by recognizing pathogens through patterns of sugar moieties and neutralizing them. The lectin pathway is triggered upon binding of mannan-binding lectin (MBL) and ficolins to sugar moieties which leads to activation of the associated proteases MASP1 and MASP2. Functions as an endopeptidase and may activate MASP2 or C2 or directly activate C3 the key component of complement reaction. Isoform 2 may have an inhibitory effect on the activation of the lectin pathway of complement or may cleave IGFBP5. Also plays a role in development (PubMed:21258343)

The "MASP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MASP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets